Welcure Drugs & Pharmaceuticals Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/09/2025 ,inter alia, to consider and approve business related ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Welcure Drugs & Pharmaceuticals has informed BSE that its Board of Directors will meet on 2nd September 2025 to consider multiple key items. The Board will approve the Board's Report, Corporate Governance Report, and Management Discussion & Analysis for FY ending 31st March 2025, along with the 33rd AGM notice, date, venue, and book closure. It will also appoint a new Statutory Auditor, M/s. Sarang Shivajirao Chavan & Associates, to fill a casual vacancy caused by the resignation of the previous auditor. Additionally, the Board proposes raising the FPI/FII/FDI/NRI investment cap to 49% of paid-up capital and increasing the threshold for loans, guarantees, and investments under Section 186 of the Companies Act. M/s. Vishakha Agarwal & Associates will be appointed as Secretarial Auditor for five years (FY2025-26 to FY2029-30) and also as Scrutinizer for the AGM e-voting process.
Shareholders should note the auditor change (due to a casual vacancy from the previous auditor's resignation) and the proposed increase in foreign investment limit to 49%, which could improve stock liquidity and attract foreign institutional interest. The AGM-related items suggest upcoming annual results approval, and the Section 186 limit hike may enable the company to make larger investments or lend more freely.